The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 07, 2024
Filed:
Feb. 01, 2021
Applicant:
Gensun Biopharma Inc., Newbury Park, CA (US);
Inventors:
Margaret Karow, Newbury Park, CA (US);
Richard Yau, Newbury Park, CA (US);
Jackie Sheng, Newbury Park, CA (US);
Assignee:
Gensun Biopharma Inc., Newbury Park, CA (US);
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3092 (2013.01); A61K 45/06 (2013.01); C07K 16/2809 (2013.01); C07K 16/2878 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01);
Abstract
Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.